Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.
about
Design and pre-clinical evaluation of a universal HIV-1 vaccineProtective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccineImmunoinformatics comes of ageAn alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells.Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesStructure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data setStructural Characterization of HIV gp41 with the Membrane-proximal External RegionA next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodiesHuman Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B EnvelopeStructure of a V3-containing HIV-1 gp120 coreHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesProgress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Structural analysis of a highly glycosylated and unliganded gp120-based antigen using mass spectrometry.Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device.A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferretsDefining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications.Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.Coping with viral diversity in HIV vaccine design.HIV-1 group M conserved elements vaccine.Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility.Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region.Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine.HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificitiesImmunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizingVaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions.Generation and characterization of an HIV-1 subtype C transmitted and early founder virus consensus sequence.Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrumCharacterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvantsChallenges in the design of a T cell vaccine in the context of HIV-1 diversity.The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.Use of RT-defective HIV virions: new tool to evaluate specific response in chronic asymptomatic HIV-infected individualsComparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaquesCross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogenAntibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heteroloRestricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African womenA multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.Innate activation of MDC and NK cells in high-risk HIV-1-exposed seronegative IV-drug users who share needles when compared with low-risk nonsharing IV-drug user controls.Emerging vaccine informatics.
P2860
Q21092234-324923B3-6C47-4A1E-812C-DEAFBECCA873Q21131325-8A1C8DDE-7189-417C-9D91-1EA31C60AA42Q21145682-2E49E064-9854-4FD7-8EBA-1E9BCBF191BBQ25256583-503F21E5-9286-46B4-9678-F25D152E2AD5Q27489000-CBCB0BFB-2127-4D25-8C65-C469B28A8260Q27650903-98AF014B-5B50-4653-B13D-19703E89B41DQ27662117-C2C65DDC-6E12-46AF-958F-01D448D53204Q28299280-112B1B86-FE63-4C2B-A8DC-B6E366217C14Q29307502-5DDEBFF9-4FD7-44EC-9F49-A091EC165321Q29619014-40C43AD0-FFE2-4EE4-A989-B062D0B4231EQ29619015-C57B58C6-BBA5-441B-A3BD-52B534330E77Q30379200-43E22E99-EC89-414B-8650-ACD74037BE00Q30393415-A70B0823-551C-434E-B172-DB2BD90A4BBEQ30395101-9B33F657-34C7-483F-A2EB-2B42658FFE0BQ30399675-1567C299-7259-44F8-8043-C090B2A64CC8Q30410411-5D83A586-DDD8-4A4F-A14F-71B444F938F5Q31106756-1EBDA53A-BA0B-47A7-B844-D4567ED2921DQ33283060-705A5AF7-F68E-4936-A389-E037D692894DQ33308246-4E7947B9-F5E8-45FC-A494-D0AF250E96D3Q33323199-94DBB4CF-B25E-4F7E-B748-C1D8F70F0303Q33508799-5A1C1069-0B5C-489F-8FD0-3BA009745FF4Q33576984-31272D25-A067-42F6-A161-50127166F49DQ33939974-0D6F963F-B9FA-4CA7-A53C-CFA5A4A2CC4DQ33967341-B10ECBFB-906D-4D57-BFDE-B2094262DB56Q33977866-CB8BC0F6-7630-4B6D-ABBA-EB5BC1C2F27CQ34016706-4441D5B7-3CA3-419E-BAA6-44C63BC1B923Q34103170-2A87F619-334F-4BF3-BD69-EA584805CB9DQ34266252-72CF5468-63C2-4757-988F-AB9592680147Q34280115-B45F8575-BF6C-472A-8B37-A5BA8F549D81Q34302085-B7C848DD-0ABA-48F8-930C-3682300BE6F8Q34423446-0CE0B8DA-7889-408A-826A-FF72033F9289Q34610233-A28101C3-A8A8-454F-8751-33C07A7A92F0Q34630184-3705858B-FC67-4265-B0F7-9F9CF89DDEADQ34663118-B4C3F450-B671-4117-8DF9-0E83118B57E2Q34717906-F7C7F214-B0FC-422C-AE86-ABED745FD4C6Q35024202-A636AB7E-7533-4F74-AD73-1321E590F5BFQ35058698-3407D52E-5913-497F-98A4-361AFFE28929Q35076748-486F3361-1852-4855-B1D3-1E7349A89535Q35085106-8C821AA8-1336-475F-B749-EF30705FDEE0Q35100809-1E8972CE-506D-498A-82FE-0DA27FD2ADB4
P2860
Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2005
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antigenicity and immunogenicit ...... nsensus envelope glycoprotein.
@en
Antigenicity and immunogenicit ...... nsensus envelope glycoprotein.
@nl
type
label
Antigenicity and immunogenicit ...... nsensus envelope glycoprotein.
@en
Antigenicity and immunogenicit ...... nsensus envelope glycoprotein.
@nl
prefLabel
Antigenicity and immunogenicit ...... nsensus envelope glycoprotein.
@en
Antigenicity and immunogenicit ...... nsensus envelope glycoprotein.
@nl
P2093
P2860
P50
P1433
P1476
Antigenicity and immunogenicit ...... nsensus envelope glycoprotein.
@en
P2093
Benjiang Ma
Eric A Weaver
Hua-Xin Liao
Jae-Sung Yu
Julie M Decker
Laura L Sutherland
Richard M Scearce
S Munir Alam
Yingying Li
P2860
P304
P356
10.1128/JVI.79.2.1154-1163.2005
P407
P577
2005-01-01T00:00:00Z